Peter Maag, PhD, Chief Executive Officer and President
Dr. Maag has over 20 years of executive management experience in the pharmaceutical and diagnostic industry. Prior to joining CareDx, Dr. Maag was President of Novartis Diagnostics based in Emeryville, California. He headed the expansion of the unit with worldwide growth in its blood screening business and established new ventures in molecular diagnostics. Dr. Maag also led one of Novartis’ key affiliates as Country President, Germany, and lived in a dynamically-growing and emerging market as Country President, Korea. At Novartis headquarters in Switzerland, he helped launch the Infectious Diseases franchise and served as the Head of Strategy for Novartis Pharmaceuticals. Prior to joining Novartis, Dr. Maag worked for 6 years at McKinsey & Company in New Jersey and Germany, focusing on pharmaceuticals and globalization strategies. Supporting various healthcare and high tech companies in their growth efforts, he holds board and advisory positions at Phoenix, MolecularMD, and Cobaltix. Dr. Maag studied pharmaceutical sciences in Heidelberg and London, and received his PhD from the University of Berlin, Germany.
Michael Bell, Chief Financial Officer
Michael Bell brings over 20 years of international finance and accounting experience. Michael is the former CFO of Metabiota, an infectious disease risk analytics company. Previously, he served as the CFO of Singulex, a clinical diagnostics company, and has held leadership and executive positions within Novartis, including tenure as the CFO of Novartis Diagnostics, a global provider of blood screening solutions. Previously, Michael worked in public accounting at Ernst & Young and Deloitte. Michael holds a Bachelor of Science degree in Mathematics with Computing from the University of Leicester in the United Kingdom, and is a Fellow of the Institute of Chartered Accountants in England & Wales.
Anders Karlsson, M.B.A., Chief International Business Officer
Mr. Karlsson joined CareDx in April 2016. Previously he served as the Chief Executive Officer of Allenex AB, a life sciences company that developed, manufactured, marketed and sold products for safer transplantation of blood, stem cells and organs. From 2009 to 2011, he served as the Chief Executive Officer of Olerup International AB, a global distributor of molecular diagnostic products and services. From 2008 to 2009, Mr. Karlsson served as the Chief Executive Officer of AbSorber AB, a biotech company that develops products for increasing the probability of transplantation success. Prior to that, Mr. Karlsson held positions of increasing responsibility at Novartis Pharmaceuticals in Sweden, including Head of Sales, Head of Sales and Marketing, and Country President for Novartis Norway.
Mr. Karlsson studied economics at the University of Jönköping and marketing management at IHM Business School Linköping in Sweden. Mr. Karlsson received his M.B.A. from the Henley Business School at the University of Reading, United Kingdom.
Mitchell J. Nelles, PhD, Chief Operating Officer
Dr. Mitch Nelles has more than 20 years of management and research and development experience in a variety of in vitro diagnostic (IVD) technology and business areas. Dr. Nelles joined CareDx from bioMerieux Inc, where he was Vice President of North America Research and Development and responsible for product development and project management for the bacteriology, molecular diagnostics, immunodiagnostics, and hemostasis business franchises. Prior to his work at bioMerieux, Dr. Nelles served as the Vice President of R&D at TriPath Oncology (TriPath Imaging) where he led the efforts to develop molecular-based products for the diagnosis and prognosis of breast and cervical cancer. Earlier in his career, Dr. Nelles held a variety of technical and managerial positions of increasing responsibility, including Vice President, Transfusion Medicine and Immunodiagnostic Assay R&D at Ortho Clinical Diagnostics (Johnson & Johnson) where he led the worldwide research and development activities in support of the blood screening, blood typing, immunodiagnostic, and RhoGAM business franchises. Dr. Nelles received his bachelor’s degree from Rutgers College in biological sciences, his PhD in immunology/biomedical sciences from the University of Texas, Health Sciences Center at Dallas (UTHSCD)/Southwestern Medical School, and completed postdoctoral training in immune regulation at Brandeis University.
John J. Sninsky, Ph.D., Chief Scientific Officer
Dr. John Sninsky brings more than 30 years of diagnostic experience to CareDx, having served in a variety of increasingly senior roles at early stage biotechnology and global pharmaceutical companies. His experience spans IVD diagnostic product and small and large CLIA settings. Most recently, Dr. Sninsky served as Vice President of Discovery Research at Celera Corporation (now part of Quest Diagnostics). His notable research work includes the pioneering application of PCR technology to virus detection, molecular oncology and early and extensive genetic association studies. He has been responsible for high throughput DNA genotyping, RNA expression, biostatistics, bioinformatics and computational biology groups with a focus on infectious disease, cardiometabolic disease and oncology. He has co-authored over 100 scientific papers and was the recipient of the Hoffmann‐La Roche R & D Prize in 1997 for his efforts in applying PCR to virology and developing assays for measuring viral load in HIV-infected individuals, as well as the Centers for Disease Control (CDC) Charles C. Shepherd Science Award in 1988 and the Pan American Society for Clinical Virology Award in 1992. Dr. Sninsky received a bachelor’s degree in biology from Bates College and a Ph.D. in biology from Purdue University. He was a postdoctoral fellow in Genetics and Medicine at Stanford University School of Medicine. Early in Dr. Sninsky’s career, he was on the faculty at Albert Einstein College of Medicine (AECOM) in the Department of Microbiology and Immunology with a joint appointment in the Department of Molecular Biology and a member of the AECOM Liver and Cancer Centers.
Todd Whitson, Chief Commercial Officer
Todd Whitson brings over 15 years of healthcare sales experience in both genetics and molecular diagnostics. As Vice President of Sales at Genzyme Genetics he helped to drive the success of the company that eventually led to an acquisition by LabCorp. He was then asked to lead up the combined, integrated oncology business unit across all of LabCorp. Mr. Whitson most recently served as the Vice President of Commercial Operations at Ariosa Diagnostics, which is now part of the Roche Group. Mr. Whitson was the first commercial hire at Ariosa and built the organization from a small, private company to a leader in the field of Non-Invasive Prenatal Testing (NIPT) based on cell-free DNA technology and next-generation sequencing. Mr. Whitson received a BA in Economics/Business and Psychology from Lafayette College, and a MA in Sports Administration from the University of Richmond.
James Yee, MD, PhD, Executive Vice President and Chief Medical Officer
Dr. James Yee brings more than 25 years of research and development experience. Most recently, Dr. Yee served as Vice President and Head of Development for Celera Genomics, where he built the development organization at Celera South San Francisco and led clinical research and therapeutic development activities for cancer and immune-mediated inflammatory diseases. Prior to his work at Celera, Dr. Yee served as Vice President of Clinical and Pre-Clinical Research for the Inflammatory and Viral Diseases Unit at Roche Pharmaceuticals. In this role, he led the team responsible for selecting and evaluating compounds for clinical drug development and oversaw groups responsible for toxicology, drug metabolism, pharmacokinetics, bioanalytical chemistry, analytical chemistry, formulations, regulatory affairs, project management, and clinical research. Earlier in his career, Dr. Yee held a variety of research and development positions of increasing responsibility at Syntex Corporation, including Vice President and Director of the Institute for Clinical Medicine. Dr. Yee received his bachelor’s degree from the University of California at Berkeley in electrical engineering and computer science. Dr. Yee went on to earn a PhD in biophysics at University of California at Berkeley. He attended the University of California, Los Angeles School of Medicine, where he earned his medical degree, and he is board certified in internal medicine.